DB:PSH

Stock Analysis Report

Executive Summary

Sernova Corp., a clinical-stage regenerative medicine therapeutics company, focuses on the development and commercializing of its proprietary Cell Pouch and associated technologies, including therapeutic cells and local immune protection.


Snowflake Analysis

Adequate balance sheet with weak fundamentals.

Share Price & News

How has Sernova's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: PSH's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

1.4%

PSH

11.3%

DE Biotechs

7.1%

DE Market


1 Year Return

-17.0%

PSH

-5.1%

DE Biotechs

-17.5%

DE Market

Return vs Industry: PSH underperformed the German Biotechs industry which returned -5.1% over the past year.

Return vs Market: PSH matched the German Market which returned -17.5% over the past year.


Shareholder returns

PSHIndustryMarket
7 Day1.4%11.3%7.1%
30 Day-27.0%-8.0%-20.0%
90 Day-39.2%-22.7%-26.1%
1 Year-17.0%-17.0%-4.9%-5.1%-15.0%-17.5%
3 Year-55.5%-55.5%17.7%16.4%-18.8%-25.8%
5 Year-42.1%-42.1%-5.1%-7.5%-17.9%-29.2%

Price Volatility Vs. Market

How volatile is Sernova's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Sernova undervalued compared to its fair value and its price relative to the market?

6.28x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate PSH's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate PSH's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: PSH is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: PSH is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate PSH's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: PSH is overvalued based on its PB Ratio (6.3x) compared to the DE Biotechs industry average (3.6x).


Next Steps

Future Growth

How is Sernova forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

79.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: PSH is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: PSH is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: PSH is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if PSH's revenue is forecast to grow faster than the German market.

High Growth Revenue: Insufficient data to determine if PSH's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if PSH's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Sernova performed over the past 5 years?

-8.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: PSH is currently unprofitable.

Growing Profit Margin: PSH is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: PSH is unprofitable, and losses have increased over the past 5 years at a rate of -8.8% per year.

Accelerating Growth: Unable to compare PSH's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: PSH is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (8.7%).


Return on Equity

High ROE: PSH has a negative Return on Equity (-123.1%), as it is currently unprofitable.


Next Steps

Financial Health

How is Sernova's financial position?


Financial Position Analysis

Short Term Liabilities: PSH's short term assets (CA$3.9M) exceed its short term liabilities (CA$472.0K).

Long Term Liabilities: PSH has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: PSH is debt free.

Reducing Debt: PSH has not had any debt for past 5 years.


Balance Sheet

Inventory Level: PSH has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if PSH's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: PSH has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: PSH has less than a year of cash runway if free cash flow continues to reduce at historical rates of -17.4% each year


Next Steps

Dividend

What is Sernova's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate PSH's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate PSH's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if PSH's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if PSH's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of PSH's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

10.8yrs

Average board tenure


CEO

Philip Toleikis

10.92s

Tenure

CA$360,000

Compensation

Dr. Philip M. Toleikis, B.A., M.Sc., Ph.D., has been the Chief Executive Officer and the President of Sernova Corp. since April 28, 2009. Dr. Toleikis is a seasoned and Experienced biotechnology executive, ...


CEO Compensation Analysis

Compensation vs Market: Philip's total compensation ($USD255.80K) is below average for companies of similar size in the German market ($USD432.27K).

Compensation vs Earnings: Philip's compensation has been consistent with company performance over the past year.


Board Members

NamePositionTenureCompensationOwnership
Philip Toleikis
President10.92yrsCA$360.00k2.65% CA$398.6k
James Parsons
Independent Director7.92yrsCA$21.25k0.11% CA$16.5k
Frank Holler
Independent Chairman5yrsCA$31.25k0.13% CA$19.2k
Norman C. Wong
Member of Scientific Advisory Board13.67yrsno datano data
Jeffrey Bacha
Independent Director11.42yrsCA$23.75k0.29% CA$43.2k
Jannette Dufour
Member of Scientific Advisory Board13.58yrsno datano data
George King
Member of Scientific Advisory Boardno datano datano data
Clive Patience
Member of Scientific Advisory Board13.25yrsno datano data
Steven Paraskevas
Member of Scientific Advisory Board9.25yrsno datano data
David Lillicrap
Member of Scientific Advisory Board1.17yrsno datano data

10.8yrs

Average Tenure

54yo

Average Age

Experienced Board: PSH's board of directors are seasoned and experienced ( 10.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 12.8%.


Top Shareholders

Company Information

Sernova Corp.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Sernova Corp.
  • Ticker: PSH
  • Exchange: DB
  • Founded:
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: CA$23.513m
  • Listing Market Cap: CA$15.068m
  • Shares outstanding: 195.95m
  • Website: https://www.sernova.com

Location

  • Sernova Corp.
  • 700 Collip Circle
  • Suite 114
  • London
  • Ontario
  • N6G 4X8
  • Canada

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
SVATSXV (TSX Venture Exchange)YesCommon SharesCACADFeb 2000
SEOV.FOTCPK (Pink Sheets LLC)YesCommon SharesUSUSDFeb 2000
PSHDB (Deutsche Boerse AG)YesCommon SharesDEEURFeb 2000

Biography

Sernova Corp., a clinical-stage regenerative medicine therapeutics company, focuses on the development and commercializing of its proprietary Cell Pouch and associated technologies, including therapeutic cells and local immune protection. The company is developing a Cell Pouch system that is in Phase I/II clinical trial for the treatment of type-1 diabetes. Its Cell Pouch system is a medical device designed to create a vascularized tissue environment for the transplantation and engraftment of therapeutic cells for the treatment of chronic diseases, such as diabetes, hemophilia A, and thyroid disease. The company is headquartered in London, Canada. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/03/29 23:32
End of Day Share Price2020/03/27 00:00
Earnings2020/01/31
Annual Earnings2019/10/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.